Cochrane · systematic review · CD003719
Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
Youssef, MA, Abou‐Setta, AM, Lam, WS · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 10%Very low 4 · 40%Low 2 · 20%Moderate 3 · 30%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRhCG compared to uhCG for final oocyte maturation triggering in IVF and ICSI cycles
Population: women undergoing final oocyte maturation triggering in IVF and ICSI cycles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ongoing pregnancy/live birth rate per woman RhCG vs uhCG | OR 1.15 [0.89, 1.49] | 7 studies · 1136 participants | Moderate |
OHSS per woman ‐ moderate to severe OHSS RhCG vs uhCG | OR 1.76 [0.37, 8.45] | 3 studies · 417 participants | Low |
Clinical pregnancy rate per woman RhCG vs uhCG | OR 1.06 [0.87, 1.29] | 13 studies · 1806 participants | Moderate |
Miscarriage rate per woman RhCG vs uhCG | OR 0.72 [0.41, 1.25] | 9 studies · 1347 participants | Low |
Adverse events per woman RhCG vs uhCG | OR 0.52 [0.35, 0.76] | 5 studies · 561 participants | Moderate |
RhLH compared to uhCG for final oocyte maturation triggering in IVF and ICSI cycles
Population: women undergoing final oocyte maturation triggering in IVF and ICSI cycles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ongoing pregnancy/live birth rate per woman RhLH vs uhCG | OR 0.95 [0.51, 1.78] | 2 studies · 289 participants | Very low Downgraded: risk of bias |
OHSS per woman ‐ Moderate OHSS RhLH vs uhCG | OR 0.83 [0.4, 1.7] | 2 studies · 289 participants | Very low Downgraded: risk of bias |
Clinical pregnancy rate per woman RhLH vs uhCG | OR 0.94 [0.54, 1.64] | 2 studies · 289 participants | Very low Downgraded: risk of bias |
Miscarriage rate per woman RhLH vs uhCG | OR 0.95 [0.38, 2.4] | 2 studies · 280 participants | Very low Downgraded: risk of bias |
Adverse events per woman RhLH vs uhCG | no estimate extracted | 1 study · 259 participants | Ungraded |
rhCG versus uhCG for triggering ovulation for final oocyte maturation triggering in IVF and ICSI cycles
Population: patients with final oocyte maturation triggering in IVF and ICSI cycles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ongoing pregnancy / live birth rate per woman rhCG vs uhCG | OR 1.04 [0.79, 1.37] | 6 studies · 1019 participants | High |
Clinical pregnancy rate per woman rhCG vs uhCG | OR 1.28 [1, 1.65] | 8 studies · 1206 participants | High |
Miscarriage rate per woman rhCG vs uhCG | OR 0.69 [0.41, 1.18] | 7 studies · 1106 participants | High |
Severe OHSS per woman rhCG vs uhCG | OR 1.49 [0.54, 4.1] | 3 studies · 549 participants | Moderate |
Adverse events per woman rhCG vs uhCG | OR 0.39 [0.25, 0.61] | 3 studies · 374 participants | High |
rhLH compared to uhCG for final oocyte maturation triggering in IVF and ICSI cycles
Population: patients with final oocyte maturation triggering in IVF and ICSI cycles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ongoing pregnancy / live birth rate per woman rhLH vs uhCG | OR 0.94 [0.5, 1.76] | 2 studies · 280 participants | Low Downgraded: risk of bias |
Clinical pregnancy rate per woman rhLH vs uhCG | OR 0.93 [0.53, 1.63] | 2 studies · 280 participants | Low Downgraded: risk of bias |
Miscarriage rate per woman rhLH vs uhCG | OR 0.94 [0.37, 2.38] | 2 studies · 280 participants | Low Downgraded: risk of bias |
Severe OHSS rhLH vs uhCG | OR 0.82 [0.39, 1.69] | 2 studies · 280 participants | Low Downgraded: risk of bias |
Adverse events per woman rhLH vs uhCG | OR 0.7 [0.42, 1.16] | 1 study · 250 participants | Moderate |